Harshit Garg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Harshit Garg has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
Dharam Kaushik
Department of Urology, Houston Methodist Hospital, Houston, Texas, USA
7 shared publicationsAhmed M. Mansour
Department of Urology, the University of Texas Health, San Antonio, Texas
5 shared publications- Deepak Kumar Pruthi
Department of Urology, University of Texas Health, San Antonio, TX
5 shared publications Hanzhang Wang
Department of Urology University of Texas Health San Antonio TX USA
5 shared publications- Michael A. Liss
Department of Urology, University of Texas Health Science Center, San Antonio, Texas
5 shared publications - Mukund Bhandari
Greehey Children’s Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas
5 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (12)
Medical therapy of MASLD – consequences of the paradigm shift from histology to non-invasive tests
- 3 September 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (12)
Open AccessMedical therapy of MASLD – consequences of the paradigm shift from histology to non-invasive tests
- Open Access
- 17 April 2026
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 7 (2) , 24
Urology Training Across Borders: An International Survey of Residents’ Experiences, Perceptions, and Expectations
Background/Objectives: Urology residency training widely varies across countries, and evidence comparing residents’ experiences at an international level is limited. This study reports the results of an international survey of urology residents from different countries worldwide, aiming to characterize training environments, educational exposure, and trainee expectations across diverse healthcare systems. Methods: A 39-item online survey was administered to urology residents during the Société Internationale d’Urologie (SIU) Regional Meeting (Florence, November 2024), assessing demographics, training exposure, educational resources, workload, satisfaction, and career perspectives. The results were compared between trainees at different postgraduate years (PGYs) to explore associations for key outcomes. Results: Overall, 208 urology residents from 21 countries completed the survey. Most residents were actively involved in research (76.4%), although confidence in independent scientific production was moderate (significantly lower among junior trainees). Surgical exposure increased with PGY, with good experience in endoscopy but limited hands-on exposure and expected autonomy in laparoscopic, robotic, and major open surgery. Despite high overall satisfaction with urology, residents described heavy workloads, inconsistent access to structured teaching and international fellowships, and a long-term shift in career expectations toward private practice. Conclusions: Urology residents worldwide report high engagement in research, strong satisfaction with their specialty choice, and interest in international mobility. Nonetheless, persistent disparities in surgical exposure, research confidence, workload, and gender representation highlight the need for competency-based curricula, structured mentorship, and improved training organization to promote equitable and high-quality urology education globally.
- 17 April 2026
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 7 (2) , 24
Open AccessUrology Training Across Borders: An International Survey of Residents’ Experiences, Perceptions, and Expectations
Background/Objectives: Urology residency training widely varies across countries, and evidence comparing residents’ experiences at an international level is limited. This study reports the results of an international survey of urology residents from different countries worldwide, aiming to characterize training environments, educational exposure, and trainee expectations across diverse healthcare systems. Methods: A 39-item online survey was administered to urology residents during the Société Internationale d’Urologie (SIU) Regional Meeting (Florence, November 2024), assessing demographics, training exposure, educational resources, workload, satisfaction, and career perspectives. The results were compared between trainees at different postgraduate years (PGYs) to explore associations for key outcomes. Results: Overall, 208 urology residents from 21 countries completed the survey. Most residents were actively involved in research (76.4%), although confidence in independent scientific production was moderate (significantly lower among junior trainees). Surgical exposure increased with PGY, with good experience in endoscopy but limited hands-on exposure and expected autonomy in laparoscopic, robotic, and major open surgery. Despite high overall satisfaction with urology, residents described heavy workloads, inconsistent access to structured teaching and international fellowships, and a long-term shift in career expectations toward private practice. Conclusions: Urology residents worldwide report high engagement in research, strong satisfaction with their specialty choice, and interest in international mobility. Nonetheless, persistent disparities in surgical exposure, research confidence, workload, and gender representation highlight the need for competency-based curricula, structured mentorship, and improved training organization to promote equitable and high-quality urology education globally.
- Open Access
- 9 January 2026
- Published by MDPI AG in Preprints.org
Urology Training Across Borders: An International Survey of Residents’ Experiences, Perceptions, and Expectations
Background/Objectives: Urology residency training widely varies across countries and evidence comparing residents’ experiences at an international level are limited. This study reports the results of an international survey of urology residents from different countries worldwide, aiming to characterize training environments, educational expo-sure, and trainee expectations across diverse healthcare systems. Methods: A 39-item online survey was administered to urology residents during the SIU Regional Meeting (Florence, November 2024), assessing demographics, training exposure, educational resources, workload, satisfaction, and career perspectives. Results were compared be-tween trainees at different postgraduate year (PGY) to explore associations for key out-comes. Results: Overall, 208 urology residents from 21 countries completed the survey. Most residents were actively involved in research (76.4%), although confidence in in-dependent scientific production was moderate (significantly lower among junior trainees). Surgical exposure increased with PGY, with good experience in endoscopy but limited hands-on exposure and expected autonomy in laparoscopic, robotic, and major open surgery. Despite high overall satisfaction with urology, residents described heavy workloads, inconsistent access to structured teaching and international fellowships, and a long-term shift in career expectations toward private practice. Conclusions: Urology residents worldwide report high engagement in research, strong satisfaction with their specialty choice, and interest in international mobility. Nonetheless, persistent disparities in surgical exposure, research confidence, workload, and gender representation highlight the need for competency-based curricula, structured mentorship, and improved training organization to promote equitable and high-quality urology education globally.
- 9 January 2026
- Published by MDPI AG in Preprints.org
Open AccessUrology Training Across Borders: An International Survey of Residents’ Experiences, Perceptions, and Expectations
Background/Objectives: Urology residency training widely varies across countries and evidence comparing residents’ experiences at an international level are limited. This study reports the results of an international survey of urology residents from different countries worldwide, aiming to characterize training environments, educational expo-sure, and trainee expectations across diverse healthcare systems. Methods: A 39-item online survey was administered to urology residents during the SIU Regional Meeting (Florence, November 2024), assessing demographics, training exposure, educational resources, workload, satisfaction, and career perspectives. Results were compared be-tween trainees at different postgraduate year (PGY) to explore associations for key out-comes. Results: Overall, 208 urology residents from 21 countries completed the survey. Most residents were actively involved in research (76.4%), although confidence in in-dependent scientific production was moderate (significantly lower among junior trainees). Surgical exposure increased with PGY, with good experience in endoscopy but limited hands-on exposure and expected autonomy in laparoscopic, robotic, and major open surgery. Despite high overall satisfaction with urology, residents described heavy workloads, inconsistent access to structured teaching and international fellowships, and a long-term shift in career expectations toward private practice. Conclusions: Urology residents worldwide report high engagement in research, strong satisfaction with their specialty choice, and interest in international mobility. Nonetheless, persistent disparities in surgical exposure, research confidence, workload, and gender representation highlight the need for competency-based curricula, structured mentorship, and improved training organization to promote equitable and high-quality urology education globally.
- Top Cited PapersOpen Access
- 7 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2519
The Current Landscape of Clinical Trials
Background/Objectives: Clinical trials are essential in the development of new medical treatments, offering crucial data on their safety and effectiveness. Methods: This study provides a comprehensive analysis of clinical trials registered on ClinicalTrials.gov, examining the current landscape, challenges, and innovations that have shaped the field over the past century. Data were extracted on 7 March 2025 and analyzed to identify patterns in trial design, sponsorship, participant demographics, and geographical distribution. Results: The analysis reveals a continuous increase in clinical trial registrations, peaking in 2021, driven by the COVID-19 pandemic. Most trials focus on cancer, reflecting its global burden, with randomized controlled trials (RCTs) being the most common study design. However, challenges persist, including underrepresentation of certain demographics, limited global distribution, and insufficient reporting of trial results. Additionally, the underrepresentation of pediatric, elderly, and minority populations in trials limits the generalizability of findings. Conclusions: The analysis underscores the need for more inclusive and globally distributed research to address disparities in health outcomes.
- 7 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2519
Top Cited PapersOpen AccessThe Current Landscape of Clinical Trials
Background/Objectives: Clinical trials are essential in the development of new medical treatments, offering crucial data on their safety and effectiveness. Methods: This study provides a comprehensive analysis of clinical trials registered on ClinicalTrials.gov, examining the current landscape, challenges, and innovations that have shaped the field over the past century. Data were extracted on 7 March 2025 and analyzed to identify patterns in trial design, sponsorship, participant demographics, and geographical distribution. Results: The analysis reveals a continuous increase in clinical trial registrations, peaking in 2021, driven by the COVID-19 pandemic. Most trials focus on cancer, reflecting its global burden, with randomized controlled trials (RCTs) being the most common study design. However, challenges persist, including underrepresentation of certain demographics, limited global distribution, and insufficient reporting of trial results. Additionally, the underrepresentation of pediatric, elderly, and minority populations in trials limits the generalizability of findings. Conclusions: The analysis underscores the need for more inclusive and globally distributed research to address disparities in health outcomes.
- Open Access
- 6 September 2024
- Published by MDPI AG in Preprints.org
The Current Landscape of Clinical Trials
Clinical trials are essential in the development of new medical treatments, offering crucial data on their safety and effectiveness. This study provides a comprehensive analysis of clinical trials registered on ClinicalTrials.gov, examining trends, challenges, and innovations that have shaped the field over the past century. Data were extracted on July 15, 2024, and analyzed to identify patterns in trial design, sponsorship, participant demographics, and geographical distribution. The analysis reveals a significant increase in clinical trial registrations, peaking in 2021, driven by the COVID-19 pandemic. Most trials focus on cancer, reflecting its global burden, and are predominantly interventional, with randomized controlled trials (RCTs) being the most common study design. However, challenges persist, including underrepresentation of certain demographics, limited global distribution, and insufficient reporting of trial results. Additionally, the underrepresentation of pediatric, elderly, and minority populations in trials limits the generalizability of findings. The analysis underscores the need for more inclusive and globally distributed research to address disparities in health outcomes.
- 6 September 2024
- Published by MDPI AG in Preprints.org
Open AccessThe Current Landscape of Clinical Trials
Clinical trials are essential in the development of new medical treatments, offering crucial data on their safety and effectiveness. This study provides a comprehensive analysis of clinical trials registered on ClinicalTrials.gov, examining trends, challenges, and innovations that have shaped the field over the past century. Data were extracted on July 15, 2024, and analyzed to identify patterns in trial design, sponsorship, participant demographics, and geographical distribution. The analysis reveals a significant increase in clinical trial registrations, peaking in 2021, driven by the COVID-19 pandemic. Most trials focus on cancer, reflecting its global burden, and are predominantly interventional, with randomized controlled trials (RCTs) being the most common study design. However, challenges persist, including underrepresentation of certain demographics, limited global distribution, and insufficient reporting of trial results. Additionally, the underrepresentation of pediatric, elderly, and minority populations in trials limits the generalizability of findings. The analysis underscores the need for more inclusive and globally distributed research to address disparities in health outcomes.
- Open Access
- 1 January 2024
- Published by Medknow in UroCancer Clinics of India
- Vol. 2 (1) , 37-44
Future Landscape in High-risk Prostate Cancer and Metastatic Prostate Cancer
Summary: The management of high-risk and advanced prostate cancer had a major paradigm shift over the past decade. From the Huggins’ era of sole androgen deprivation therapy (ADT), the management has evolved to novel androgen receptor signaling inhibitors (ARSI), chemotherapy, targeted molecular, immunotherapy, and radiotheranostics. The management of advanced prostate cancer is broadly studied under metastatic hormone or castration-sensitive prostate cancer (mCSPC) or metastatic castration-resistant prostate cancer (mCRPC). The mCSPC has evolved from mere ADT to the use of abiraterone, enzalutamide, and docetaxel-based chemotherapy and the burning conflict of treatment intensification with triplet therapy. Various novel agents, such as poly (ADP-ribose) polymerase inhibitors (PARPIs) and radiotheranostics, are being explored in the management of mCSPC. The management of mCRPC has evolved from mitoxantrone to docetaxel-based therapy, novel ARSI therapy, PARPI, 177 lutetium-prostate-specific membrane antigen-617, or novel-targeted therapy.
- 1 January 2024
- Published by Medknow in UroCancer Clinics of India
- Vol. 2 (1) , 37-44
Open AccessFuture Landscape in High-risk Prostate Cancer and Metastatic Prostate Cancer
Summary: The management of high-risk and advanced prostate cancer had a major paradigm shift over the past decade. From the Huggins’ era of sole androgen deprivation therapy (ADT), the management has evolved to novel androgen receptor signaling inhibitors (ARSI), chemotherapy, targeted molecular, immunotherapy, and radiotheranostics. The management of advanced prostate cancer is broadly studied under metastatic hormone or castration-sensitive prostate cancer (mCSPC) or metastatic castration-resistant prostate cancer (mCRPC). The mCSPC has evolved from mere ADT to the use of abiraterone, enzalutamide, and docetaxel-based chemotherapy and the burning conflict of treatment intensification with triplet therapy. Various novel agents, such as poly (ADP-ribose) polymerase inhibitors (PARPIs) and radiotheranostics, are being explored in the management of mCSPC. The management of mCRPC has evolved from mitoxantrone to docetaxel-based therapy, novel ARSI therapy, PARPI, 177 lutetium-prostate-specific membrane antigen-617, or novel-targeted therapy.
- Open Access
- 1 September 2023
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 1 (9)
Clinically Significant Prostate Cancer in Men With High-Grade Intraepithelial Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation
Purpose: The clinical management of Atypical Small Acinar Proliferation (ASAP) and High-Grade Prostate Intraepithelial Neoplasia (HGPIN) varies significantly. The aim of this study was to characterize the incidence and natural history of ASAP and HGPIN lesions to optimize follow-up strategies. Materials and Methods: A retrospective analysis of patients at a VA Medical Center who underwent a prostate needle biopsy between 1988 and 2017 was performed. The pathological lesions were grouped as ASAP, HGPIN, and ASAP & HGPIN. The primary outcome was the incidence of clinically significant prostate cancer (csPCa) defined as grade group ≥2 prostate cancer. Results: Of 6104 patients screened, 312 patients included having ASAP (n = 70, 1.1%), HGPIN (n = 222, 3.6%), or ASAP & HGPIN (n = 20, 0.3%). Follow-up biopsy was performed in 99.3% of patients. The incidence of prostate cancer in ASAP, HGPIN, or ASAP & HGPIN groups was 46.3%, 37%, and 68.4%, respectively (P = .03). However, the rate of csPCa was similar across the 3 groups (10.1% in ASAP, 10.3% in HGPIN, and 10.5% in ASAP & HGPIN, P = .6). The median time to cancer diagnosis was significantly shorter for patients with ASAP (2.8 years for ASAP, 4.9 years for HGPIN, and 1.5 years for ASAP & HGPIN, P = .001); however, there was no significant difference in time to diagnosis of csPCa between the various groups (P = .7). Conclusion: Both ASAP and HGPIN have a low risk of progression to csPCa. This, coupled with a prolonged time to any cancer diagnosis, suggests that immediate repeat biopsy might not be necessary among these patients.
- 1 September 2023
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 1 (9)
Open AccessClinically Significant Prostate Cancer in Men With High-Grade Intraepithelial Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation
Purpose: The clinical management of Atypical Small Acinar Proliferation (ASAP) and High-Grade Prostate Intraepithelial Neoplasia (HGPIN) varies significantly. The aim of this study was to characterize the incidence and natural history of ASAP and HGPIN lesions to optimize follow-up strategies. Materials and Methods: A retrospective analysis of patients at a VA Medical Center who underwent a prostate needle biopsy between 1988 and 2017 was performed. The pathological lesions were grouped as ASAP, HGPIN, and ASAP & HGPIN. The primary outcome was the incidence of clinically significant prostate cancer (csPCa) defined as grade group ≥2 prostate cancer. Results: Of 6104 patients screened, 312 patients included having ASAP (n = 70, 1.1%), HGPIN (n = 222, 3.6%), or ASAP & HGPIN (n = 20, 0.3%). Follow-up biopsy was performed in 99.3% of patients. The incidence of prostate cancer in ASAP, HGPIN, or ASAP & HGPIN groups was 46.3%, 37%, and 68.4%, respectively (P = .03). However, the rate of csPCa was similar across the 3 groups (10.1% in ASAP, 10.3% in HGPIN, and 10.5% in ASAP & HGPIN, P = .6). The median time to cancer diagnosis was significantly shorter for patients with ASAP (2.8 years for ASAP, 4.9 years for HGPIN, and 1.5 years for ASAP & HGPIN, P = .001); however, there was no significant difference in time to diagnosis of csPCa between the various groups (P = .7). Conclusion: Both ASAP and HGPIN have a low risk of progression to csPCa. This, coupled with a prolonged time to any cancer diagnosis, suggests that immediate repeat biopsy might not be necessary among these patients.
- Open Access
- 10 June 2023
- Published by Springer Nature in Research Square
Three Decades of Novel Drug Approval: A Comprehensive Analysis
This study analyzes FDA approved novel therapeutic drugs over the past three decades to identify trends in drug development. The study collected and analyzed information on drug attributes, approval types, and targeted diseases for drugs approved between 1991 and 2023. Results show that the FDA has approved 1096 novel drugs, with 79% being new molecular entities (NME) and 21% being biologics. Priority review was granted to 46% of the drugs, and 34% were given orphan status. Breakthrough therapy status was granted for 11% of the drugs, and 7% received accelerated approval. Novartis sponsored the highest number of approved drugs, with 54 in total. Around 22% of the drugs approved were cancer-related, with lung and breast cancer being the top two types. The study concludes that FDA's regulatory incentives could facilitate the pharmaceutical industry in addressing new challenges and bringing innovation in the future. A user-friendly web portal and application is in development to allow user to access updated comprehensive information of novel drugs all in one place.
- 10 June 2023
- Published by Springer Nature in Research Square
Open AccessThree Decades of Novel Drug Approval: A Comprehensive Analysis
This study analyzes FDA approved novel therapeutic drugs over the past three decades to identify trends in drug development. The study collected and analyzed information on drug attributes, approval types, and targeted diseases for drugs approved between 1991 and 2023. Results show that the FDA has approved 1096 novel drugs, with 79% being new molecular entities (NME) and 21% being biologics. Priority review was granted to 46% of the drugs, and 34% were given orphan status. Breakthrough therapy status was granted for 11% of the drugs, and 7% received accelerated approval. Novartis sponsored the highest number of approved drugs, with 54 in total. Around 22% of the drugs approved were cancer-related, with lung and breast cancer being the top two types. The study concludes that FDA's regulatory incentives could facilitate the pharmaceutical industry in addressing new challenges and bringing innovation in the future. A user-friendly web portal and application is in development to allow user to access updated comprehensive information of novel drugs all in one place.
- 9 March 2023
- Published by Wiley in BJU International
- Vol. 132 (1) , 9-30
Robot‐assisted retroperitoneal lymph node dissection: a systematic review of perioperative outcomes
Objective: To assess the safety and feasibility of robot‐assisted retroperitoneal lymph node dissection (R‐RPLND) and to compare the perioperative outcomes of R‐RPLND with open RPLND (O‐RPLND), as RPLND forms an integral part of the management of testis cancer and R‐RPLND is a minimally invasive treatment option for this disease. Materials and Methods: The PubMed ® , Scopus ® , Cochrane Central Register of Controlled Trials, and Web of Science™ databases were searched for studies reporting perioperative outcomes of primary and post‐chemotherapy R‐RPLND and studies comparing R‐RPLND with O‐RPLND. Results: The search yielded 42 articles describing R‐RPLND, including five comparative studies. The systematic review included 4222 patients (single‐arm studies, n = 459; comparative studies, n = 3763). Of 459 patients in the single‐arm studies, 271 underwent primary R‐RPLND and 188 underwent post‐chemotherapy R‐RPLND. For primary R‐RPLND, the operative time ranged from 175 to 540 min and the major complication rate was 4.1%. For post‐chemotherapy R‐RPLND, the operative time ranged from 134 to 550 min and the major complication rate was 8.5%. The conversion rate to open surgery was 2.2% in primary R‐RPLND and 9.0% in post‐chemotherapy R‐RPLND. In comparison with O‐RPLND, R‐RPLND was associated with a lower transfusion rate (14.5% vs 0.9%, P < 0.001) and a lower complication rate (18.5% vs 7.8%, P = 0.002). Conclusion: Robot‐assisted RPLND has acceptable perioperative outcomes in both the primary and post‐chemotherapy settings but a notable rate of conversion to open surgery in the post‐chemotherapy setting. Compared with O‐RPLND, R‐RPLND is associated with a lower transfusion rate and fewer overall complications. Given the potential impact of selection bias, the optimal patient selection criteria for R‐RPLND remain to be elucidated.
- 9 March 2023
- Published by Wiley in BJU International
- Vol. 132 (1) , 9-30
Robot‐assisted retroperitoneal lymph node dissection: a systematic review of perioperative outcomes
Objective: To assess the safety and feasibility of robot‐assisted retroperitoneal lymph node dissection (R‐RPLND) and to compare the perioperative outcomes of R‐RPLND with open RPLND (O‐RPLND), as RPLND forms an integral part of the management of testis cancer and R‐RPLND is a minimally invasive treatment option for this disease. Materials and Methods: The PubMed ® , Scopus ® , Cochrane Central Register of Controlled Trials, and Web of Science™ databases were searched for studies reporting perioperative outcomes of primary and post‐chemotherapy R‐RPLND and studies comparing R‐RPLND with O‐RPLND. Results: The search yielded 42 articles describing R‐RPLND, including five comparative studies. The systematic review included 4222 patients (single‐arm studies, n = 459; comparative studies, n = 3763). Of 459 patients in the single‐arm studies, 271 underwent primary R‐RPLND and 188 underwent post‐chemotherapy R‐RPLND. For primary R‐RPLND, the operative time ranged from 175 to 540 min and the major complication rate was 4.1%. For post‐chemotherapy R‐RPLND, the operative time ranged from 134 to 550 min and the major complication rate was 8.5%. The conversion rate to open surgery was 2.2% in primary R‐RPLND and 9.0% in post‐chemotherapy R‐RPLND. In comparison with O‐RPLND, R‐RPLND was associated with a lower transfusion rate (14.5% vs 0.9%, P < 0.001) and a lower complication rate (18.5% vs 7.8%, P = 0.002). Conclusion: Robot‐assisted RPLND has acceptable perioperative outcomes in both the primary and post‐chemotherapy settings but a notable rate of conversion to open surgery in the post‐chemotherapy setting. Compared with O‐RPLND, R‐RPLND is associated with a lower transfusion rate and fewer overall complications. Given the potential impact of selection bias, the optimal patient selection criteria for R‐RPLND remain to be elucidated.
- 2 February 2023
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 11 (3) , 595-604.e2
Patency outcomes of primary inferior vena cava repair in radical nephrectomy and tumor thrombectomy
- 2 February 2023
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 11 (3) , 595-604.e2
Patency outcomes of primary inferior vena cava repair in radical nephrectomy and tumor thrombectomy